Barrons.com11d agoneutral
AstraZeneca-Bristol Myers: The Floodgates for Biotech Mergers Are OpenEven if a megamerger fails to materialize, investors stand to benefit from a wave of M&A activity in the biopharma sector.
Actualités
Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.
46last 24h
1804last 7d
299● bullish (7d)
171● bearish (7d)
205publishers
PA Media: Money12d agoneutral
Stocks mixed as AstraZeneca merger talk dents FTSE 100The FTSE 100 index closed down 10.35 points, 0.1%, at 10,857.70.
MT Newswires15d agoneutral
AbbVie Trims Full-Year Profit Outlook Due to Apogee AcquisitionAbbVie (ABBV) lowered its full-year earnings guidance on Friday to account for the expected dilution
Motley Fool26d agoneutral
How Will AbbVie's $10.9 Billion Acquisition of Apogee Impact Its Dividend?There's no need to panic.
Quartz54d agoneutral
AbbVie acquires Apogee Therapeutics for $10.9 billionThe all-cash deal gives AbbVie access to zumilokibart, an experimental drug that could rival Dupixent in treating atopic dermatitis